Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

843 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation.
Yamada T, Azuma K, Muta E, Kim J, Sugawara S, Zhang GL, Matsueda S, Kasama-Kawaguchi Y, Yamashita Y, Yamashita T, Nishio K, Itoh K, Hoshino T, Sasada T. Yamada T, et al. Among authors: sugawara s. PLoS One. 2013 Nov 5;8(11):e78389. doi: 10.1371/journal.pone.0078389. eCollection 2013. PLoS One. 2013. PMID: 24223798 Free PMC article.
Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens.
Yamada T, Terazaki Y, Sakamoto S, Yoshiyama K, Matsueda S, Komatsu N, Waki K, Yamada A, Kawahara A, Kage M, Sugawara S, Yamashita Y, Sasada T, Takamori S, Itoh K. Yamada T, et al. Among authors: sugawara s. Int J Oncol. 2015 Jan;46(1):55-62. doi: 10.3892/ijo.2014.2699. Epub 2014 Oct 7. Int J Oncol. 2015. PMID: 25310280 Clinical Trial.
Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer.
Iwamoto Y, Mitsudomi T, Sakai K, Yamanaka T, Yoshioka H, Takahama M, Yoshimura M, Yoshino I, Takeda M, Sugawara S, Kawaguchi T, Takahashi T, Ohta M, Ichinose Y, Atagi S, Okada M, Saka H, Nakagawa K, Nakanishi Y, Nishio K. Iwamoto Y, et al. Among authors: sugawara s. Clin Cancer Res. 2015 Dec 1;21(23):5245-52. doi: 10.1158/1078-0432.CCR-14-3160. Epub 2015 Aug 7. Clin Cancer Res. 2015. PMID: 26253869 Clinical Trial.
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
Takeda M, Yamanaka T, Seto T, Hayashi H, Azuma K, Okada M, Sugawara S, Daga H, Hirashima T, Yonesaka K, Urata Y, Murakami H, Saito H, Kubo A, Sawa T, Miyahara E, Nogami N, Nakagawa K, Nakanishi Y, Okamoto I. Takeda M, et al. Among authors: sugawara s. Cancer. 2016 Apr 1;122(7):1050-9. doi: 10.1002/cncr.29893. Epub 2016 Feb 1. Cancer. 2016. PMID: 26828788 Free article. Clinical Trial.
Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer.
Takayama K, Sugawara S, Saijo Y, Maemondo M, Sato A, Takamori S, Harada T, Sasada T, Kakuma T, Kishimoto J, Yamada A, Noguchi M, Itoh K, Nakanishi Y. Takayama K, et al. Among authors: sugawara s. J Immunol Res. 2016;2016:1745108. doi: 10.1155/2016/1745108. Epub 2016 May 4. J Immunol Res. 2016. PMID: 27274999 Free PMC article. Clinical Trial.
Treatments and outcomes of advanced/recurrent non-small cell lung cancer harboring the EGFR T790M mutation: a retrospective observational study of 141 patients in Japan.
Yamane Y, Shiono A, Ishii Y, Isobe K, Miyauchi E, Kishi K, Nishino M, Sugawara S, Ko R, Koyama N, Yabuki Y, Kobayashi K. Yamane Y, et al. Among authors: sugawara s. Jpn J Clin Oncol. 2016 Dec;46(12):1135-1142. doi: 10.1093/jjco/hyw124. Epub 2016 Sep 21. Jpn J Clin Oncol. 2016. PMID: 27655904
Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer.
Sakamoto S, Yamada T, Terazaki Y, Yoshiyama K, Sugawara S, Takamori S, Matsueda S, Shichijo S, Yamada A, Noguchi M, Itoh K, Hattori N, Kohno N, Sasada T. Sakamoto S, et al. Among authors: sugawara s. Clin Lung Cancer. 2017 Nov;18(6):e385-e394. doi: 10.1016/j.cllc.2017.03.011. Epub 2017 Mar 24. Clin Lung Cancer. 2017. PMID: 28416261 Free article. Clinical Trial.
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Azuma K, Nishio M, Hayashi H, Kiura K, Satouchi M, Sugawara S, Hida T, Iwamoto Y, Inoue A, Takeda K, Ikeda S, Nakagawa T, Takeda K, Asahina S, Komatsu K, Morita S, Fukuoka M, Nakagawa K. Azuma K, et al. Among authors: sugawara s. Cancer Sci. 2018 Aug;109(8):2532-2538. doi: 10.1111/cas.13651. Epub 2018 Jun 29. Cancer Sci. 2018. PMID: 29807396 Free PMC article. Clinical Trial.
843 results